Vesicare Related Published Studies
Well-designed clinical trials related to Vesicare (Solifenacin)
A randomized, double-blind, solifenacin succinate versus placebo control, phase
4, multicenter study evaluating urinary continence after robotic assisted radical
prostatectomy. [2015]
Severity of overactive bladder symptoms and response to dose escalation in a
randomized, double-blind trial of solifenacin (SUNRISE). [2013]
Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. [2011.07]
Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study. [2011.07]
Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. [2011.07]
Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (</= 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. [2011.02]
Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder:
impact on sleep evaluated by bladder diary. [2011]
Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. [2010.10]
Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. [2010.10]
Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. [2010.07]
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. [2010.05]
Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. [2010]
Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. [2009.12]
Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. [2009.12]
Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. [2009.11]
Safety and Tolerability of Solifenacin Add-on Therapy to alpha-Blocker Treated Men With Residual Urgency and Frequency. [2009.10.16]
Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. [2009.09]
Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. [2009.01]
Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. [2008.11]
Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. [2007.09]
Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. [2007.07]
Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. [2006.09]
Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. [2006.08]
Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. [2006.06]
Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. [2006.06]
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. [2006.03]
A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. [2005.09]
Effect of age on the pharmacokinetics of solifenacin in men and women. [2005.05]
Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. [2005.03]
Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. [2005.01]
Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. [2004.11]
Pharmacokinetics and safety of solifenacin succinate in healthy young men. [2004.09]
Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. [2004.07]
Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. [2004.02]
Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. [2004.01]
Solifenacin demonstrates high absolute bioavailability in healthy men. [2004]
Well-designed clinical trials possibly related to Vesicare (Solifenacin)
Validation of the Patient Perception of Intensity of Urgency Scale in patients
with lower urinary tract symptoms associated with benign prostatic hyperplasia. [2014]
Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. [2012]
Which anticholinergic drug for overactive bladder symptoms in adults. [2012]
Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? [2011.07]
Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. [2011.05.20]
A simple validated scale to measure urgency. [2008.03]
Other research related to Vesicare (Solifenacin)
Solifenacin is able to improve the irritative symptoms after transurethral
resection of bladder tumors. [2014]
Effect of improvement in lower urinary tract symptoms on sexual function in men:
tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin. [2014]
[A combination of solifenacin succinate and naftopidil in the treatment of female
overactive bladder]. [Article in Chinese] [2013]
Solifenacin succinate versus percutaneous tibial nerve stimulation in women with
overactive bladder syndrome: results of a randomized controlled crossover study. [2013]
Reduction in the volume of water for ingesting orally disintegrating tablets of
solifenacin (Vesicare® OD), and the clinical disintegration time of Vesicare® OD
after unit-dose packaging. [2013]
Long-term safety and efficacy of two different antimuscarinics, imidafenacin and
solifenacin, for treatment of overactive bladder: a prospective randomized
controlled study. [2013]
Solifenacin for overactive bladder: a systematic review and meta-analysis. [2012]
Solifenacin may improve sleep quality in patients with overactive bladder and sleep disturbance. [2011.09]
Efficacy and tolerability of solifenacin in patients aged >/= 65 years with overactive bladder: post-hoc analysis of 2 open-label studies. [2011.01]
Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin
versus tolterodine for female overactive bladder syndrome. [2011]
Prospective open label study of solifenacin for overactive bladder in children. [2010.10]
Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. [2010.09]
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. [2010.08]
Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. [2010.06]
Solifenacin: scientific evidence in the treatment of overactive bladder. [2010.04]
Solifenacin pharmacology. [2010.01]
The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes. [2010]
Solifenacin and tolterodine are equally effective in the treatment of overactive
bladder symptoms. [2010]
Solifenacin for overactive bladder: secondary analysis of data from VENUS based
on baseline continence status. [2010]
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate
release 3 times daily: results of the VECTOR trial. [2010]
Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis. [2009.12]
Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study. [2009.10.10]
Solifenacin for therapy resistant overactive bladder. [2009.10]
Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. [2009.09.11]
Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. [2009.06]
Solifenacin succinate for the treatment of overactive bladder. [2009.03]
Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation. [2009.03]
Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study. [2009.01]
Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. [2009]
Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study. [2009]
Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. [2009]
The cost utility of solifenacin in the treatment of overactive bladder. [2009]
Clinical pharmacokinetics and pharmacodynamics of solifenacin. [2009]
[Efficacy and safety of solifenacin in daily clinical practice--clinical study phase IV] [2008.12]
Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. [2008.11]
Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. [2008.10]
The cost utility of solifenacin in the treatment of overactive bladder. [2008.08.15]
A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. [2008.08]
Solifenacin at 3 years: a review of efficacy and safety. [2008.07]
Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. [2008.06]
Solifenacin-induced small bowel pseudo-obstruction. [2008.03]
A review of solifenacin in the treatment of urinary incontinence. [2008.02]
Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial. [2008.01]
Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. [2008]
Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice. [2007.12]
Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. [2007.10]
Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. [2007.09]
Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes. [2007.04]
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. [2007.03]
Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency. [2007.01]
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. [2007.01]
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). [2006.11]
Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. [2005.09]
Other possibly related research studies
Overactive bladder treatments in early phase clinical trials. [2007.07]
Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. [2007.05]
Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? [2007.06]
Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials. [2007.08]
[How do medications used to treat urinary incontinence affect the cerebral function of the elderly?] [2007.04]
New developments in the treatment of urinary incontinente. [2006.12]
|
